Rifabutin

Generic Name
Rifabutin
Brand Names
Mycobutin, Talicia
Drug Type
Small Molecule
Chemical Formula
C46H62N4O11
CAS Number
72559-06-9
Unique Ingredient Identifier
1W306TDA6S
Background

A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.

Indication

For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

Associated Conditions
Helicobacter Pylori Infection, Mycobacterium avium complex infection, Tuberculosis (TB), Late phase Tuberculosis
Associated Therapies
-

Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study

First Posted Date
2024-12-12
Last Posted Date
2024-12-19
Lead Sponsor
Xiuli Zuo
Target Recruit Count
30
Registration Number
NCT06731023
Locations
🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

Rescue Therapy for Helicobacter Pylori Infection

First Posted Date
2023-05-25
Last Posted Date
2024-10-22
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
357
Registration Number
NCT05874544
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

🇨🇳

Shanghai Songjiang District Central Hospital, Shanghai, Shanghai, China

🇨🇳

The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, Zhejiang, China

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

First Posted Date
2023-03-13
Last Posted Date
2024-01-08
Lead Sponsor
Centers for Disease Control and Prevention
Target Recruit Count
288
Registration Number
NCT05766267
Locations
🇺🇸

TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States

🇺🇸

TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States

🇺🇸

TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States

and more 9 locations

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

First Posted Date
2022-07-14
Last Posted Date
2024-12-03
Lead Sponsor
Gilead Sciences
Target Recruit Count
18
Registration Number
NCT05458102
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC., Miami, Florida, United States

🇺🇸

Collaborative Neuroscience Research, LLC., Long Beach, California, United States

🇺🇸

Triple O Research Institute, P.A., West Palm Beach, Florida, United States

and more 2 locations

Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2020-12-17
Last Posted Date
2022-05-10
Lead Sponsor
Tourcoing Hospital
Target Recruit Count
436
Registration Number
NCT04672525
Locations
🇫🇷

CHU Reims, Reims, France

🇫🇷

CH Annecy Genevois, Pringy, France

🇫🇷

Clinique de la Sauvegarde, Lyon, France

and more 27 locations

A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

First Posted Date
2020-11-16
Last Posted Date
2024-12-10
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
129
Registration Number
NCT04630145
Locations
🇰🇷

Chonnam National University Hospital, Gwangju, Korea, Republic of

🇯🇵

St. Luke's International Hospital, Chuo ku, Japan

🇯🇵

Fukui Prefectural Hospital, Fukui-shi, Japan

and more 52 locations

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-07-14
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
13
Registration Number
NCT04470908
Locations
🇺🇸

Covance Clinical Research Unit, Daytona Beach, Florida, United States

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

First Posted Date
2020-03-17
Last Posted Date
2024-12-11
Lead Sponsor
The University of Queensland
Target Recruit Count
300
Registration Number
NCT04310930
Locations
🇦🇺

St George Hospital, Kogarah, New South Wales, Australia

🇦🇺

Austin Hospital, Heidelberg, Victoria, Australia

🇦🇺

Royal Melbourne Hospital, Parkville, Victoria, Australia

and more 47 locations

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

Phase 2
Completed
Conditions
Interventions
First Posted Date
2019-03-27
Last Posted Date
2023-10-23
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
24
Registration Number
NCT03891901
Locations
🇺🇸

Emory University DAIDS TB Non-Network CRS, Atlanta, Georgia, United States

© Copyright 2024. All Rights Reserved by MedPath